Acute Respiratory Distress Syndrome Market Size in 7MM was ~USD 940 Million in 2023, estimated DelveInsight

Posted on
by

Acute Respiratory Distress Syndrome Market Size in 7MM was ~USD 940 Million in 2023, estimated DelveInsight

DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of acute respiratory distress syndrome, historical and forecasted epidemiology, as well as the acute respiratory distress syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Explore the intricate details of the Acute Respiratory Distress Syndrome Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Acute Respiratory Distress Syndrome Market Forecast. Click here to stay ahead in healthcare innovation @ Acute Respiratory Distress Syndrome Market Size

 

Key Takeaways from the Acute Respiratory Distress Syndrome Market Report

  • June 2024:- Dompe Farmaceutici SpA– Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO)
  • May 2024:- AstraZeneca-A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen.
  • May 2024:- ONY– The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
  • According to DelveInsight’s estimates in 2023, approximately 861k incident cases of acute respiratory distress syndrome were estimated in the 7MM. These cases are anticipated to increase during the forecast period (2024-2034), driven by environmental pollutants like air pollution and toxin exposure, which elevate respiratory diseases.
  • As per DelveInsight’s analysis in 2023, there were approximately 19,193 incident cases of acute respiratory distress syndrome in Japan. Out of which the primary risk factors of acute respiratory distress syndrome involved nearly 93,819, 86,256, 34,122, 38,170, 13,603, 18,510, and, 13,410 cases of pneumonia, sepsis, trauma, aspiration, pancreatitis, others, and unknown respectively.
  • The leading Acute Respiratory Distress Syndrome Companies such as Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
  • Promising Acute Respiratory Distress Syndrome Therapies such as STSA-1002 Injection, GEn-1124, Rhu-pGSN, and others.

 

Delve deep into the Acute Respiratory Distress Syndrome Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Acute Respiratory Distress Syndrome Market Forecast. Click here to shape the future @ Acute Respiratory Distress Syndrome Epidemiology Insights

 

Acute Respiratory Distress Syndrome Overview

 Acute Respiratory Distress Syndrome (ARDS) is a serious lung condition that can occur in response to various direct or indirect injuries to the lungs. It is characterized by severe inflammation and damage to the alveoli (air sacs) in the lungs, which are responsible for exchanging oxygen and carbon dioxide between the air and the blood.

 

Acute Respiratory Distress Syndrome Epidemiology Insights

  • Total Acute Respiratory Distress Syndrome Incident cases
  • Acute Respiratory Distress Syndrome Severity-specific cases
  • Incident cases of acute respiratory distress syndrome by risk factors

 

Navigate the complexities of the Acute Respiratory Distress Syndrome Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Acute Respiratory Distress Syndrome Market Forecast. Click here to get more insights @ Acute Respiratory Distress Syndrome Treatment Market

 

Acute Respiratory Distress Syndrome Emerging Drugs

  • EB05 (paridiprubart): Edesa Biotech/Light Chain Biosciences

EB05 (paridiprubart) is a first-in-class monoclonal antibody that has been engineered to alter inflammatory signaling by binding to and blocking the activation of toll-like receptor 4 (TLR4) Its intended function is to modulate the excessive and impaired immune response linked to Acute Respiratory Distress Syndrome (ARDS). By impeding TLR4 signaling, which serves as a critical mediator of inflammation triggering acute lung injury, EB05 aims to address the pathological immune responses activated by viruses such as SARS-CoV2, SARS-CoV1, and Influenza.

EB05 has demonstrated safety in two clinical studies (>120 patients) and was able to block LPS-induced (TLR4 agonist) IL-6 release in humans. A Phase II/III trial is currently being conducted to investigate the drug candidate for the treatment of acute respiratory distress syndrome. Additionally, it is being considered as a possible course of treatment for COVID-19 hospital patients, with a December 2024 completion date anticipated.

  • Alteplase (Actilyse): Boehringer Ingelheim/ Genentech

Alteplase is the only licensed blood clot-dissolving treatment (thrombolytic) for acute ischemic stroke therapy, which is used in many stroke centers. In addition, it can be used for the treatment of acute myocardial infarction, acute massive pulmonary embolism, and catheter clearance due to thrombotic occlusion (indications vary across countries). Alteplase is marketed as Actilyse by Boehringer Ingelheim in countries outside of the US and Canada. In the US and Canada, it is marketed by Genentech. The drug candidate completed Phase II/III (TRISTARDS) to treat COVID-19 ARDS.

  • BIO-11006: BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is developing its lead compound BIO-11006 for the treatment of ARDS. Biomarck’s BIO-11006 is a novel, highly soluble, patented, 10 amino acid peptide. It acts as a MARCKS (Myristoylated alanine-rich C kinase substrate) protein inhibitor and is being developed to specifically target the MARCKS protein to inhibit cancer cell division and movement. Furthermore, it is a water-soluble, stable aerosolized anti-MARCKS peptide inhalation solution that involves aerosolized delivery of either the active drug or placebo by the “Aeroneb Pro nebulizer.” In April 2020 the company announced positive phase II results. The drug is ready to enter Phase III for the treatment of ARDS.

  • ExoFlo (DB-001): Direct Biologics

ExoFlo (DB-001) being developed by Direct Biologics is an extracellular signal product isolated from human bone marrow mesenchymal stem or stromal cells (BM-MSCs) that contains growth factors and extracellular vesicles including exosomes. It provides natural bioactive signals that downregulate inflammation, direct cellular communication, and upregulate tissue repair in humans. In April 2022, the US FDA awarded ExoFlo a Regenerative Medicine Advanced Therapy (RMAT) designation. Currently the drug candidate is being evaluated in a Phase III trial, expected to complete by March 2025.

 

Acute Respiratory Distress Syndrome Drug Market

Acute Respiratory Distress Syndrome typically involve a multi-faceted approach aimed at managing the underlying cause and supporting and preventing further complications. Corticosteroids may be prescribed in specific instances, particularly when acute respiratory distress syndrome stems from inflammatory conditions like pneumonia or sepsis. Neuromuscular blocking agents are utilized to ensure adequate sedation and paralysis in severe acute respiratory distress syndrome cases requiring mechanical ventilation, aiding in enhancing patient-ventilator synchrony and mitigating ventilator-induced lung injury.

Moreover, sedatives and analgesics play a crucial role in pain management, optimizing patient comfort, alleviating anxiety, and facilitating mechanical ventilation. Antibiotics are administered when bacterial infections are suspected or confirmed to contribute to acute respiratory distress syndrome. While diuretics are cautiously used in patients displaying signs of fluid overload to attain euvolemia, their routine usage is discouraged.

 

Unlock insights into the Acute Respiratory Distress Syndrome Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Acute Respiratory Distress Syndrome Market Forecast. Click here @ Acute Respiratory Distress Syndrome Market Drivers and Barriers

 

Acute Respiratory Distress Syndrome Therapies and Companies

  • MultiStem (HLCM051): Healios/Nobel Pharma
  • EB05 (paridiprubart): Edesa Biotech/Light Chain Biosciences
  • Remestemcel-L: Mesoblast Limited
  • Sabizabulin (Veru-111): Veru
  • Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
  • PLX-PAD: Pluristem Therapeutics
  • AVTX-002 (CERC-002): Avalo Therapeutics

 

Acute Respiratory Distress Syndrome Treatment Landscape

Treatment of acute respiratory distress syndrome is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management.

 

Gain a strategic edge in the Acute Respiratory Distress Syndrome Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Acute Respiratory Distress Syndrome Market Forecast. Click here to lead in advancements @ Acute Respiratory Distress Syndrome Clinical Trials Assessment

 

Scope of the Acute Respiratory Distress Syndrome Market Report

  • Coverage- 7MM
  • Acute Respiratory Distress Syndrome Companies- Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
  • Acute Respiratory Distress Syndrome Therapies- STSA-1002 Injection, GEn-1124, Rhu-pGSN, and others.
  • Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome Market drivers and Acute Respiratory Distress Syndrome Market Barriers
  • Acute Respiratory Distress Syndrome Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Acute Respiratory Distress Syndrome Unmet Needs, KOL’s views, Analyst’s views, Acute Respiratory Distress Syndrome Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Acute Respiratory Distress Syndrome Market Overview at a Glance

4 Methodology of Acute Respiratory Distress Syndrome Epidemiology and Market

5 Executive Summary of Acute Respiratory Distress Syndrome

6 Key Events

7 Disease Background and Overview

8 Patient Journey

9 Epidemiology and Patient Population

10 Emerging Drugs

To be continued in the report…..

12 Acute Respiratory Distress Syndrome: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/